Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9854613 | 0.83 | PDK2 (0.41) | PDK2PDK4MEN1KMT2ANPC1 | |
| SCHEMBL29360424 | 0.81 | ALOX5 (0.44) | PDK2PDK4MEN1KMT2ANPC1 | |
| SCHEMBL47009 | 0.81 | ALOX5 (0.44) | PDK2PDK4MEN1KMT2ANPC1 | |
| SCHEMBL28575606 | 0.81 | PDK2 (0.39) | PDK2PDK4MEN1KMT2ANPC1 | |
| SCHEMBL31243239 | 0.79 | ALOX5 (0.42) | PDK2PDK4MEN1KMT2ANPC1 | |
| Phosphine SCHEMBL17530281 | 0.79 | ALOX5 (0.42) | PDK2PDK4MEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL10624869 | 0.79 | ALOX5 (0.42) | PDK2PDK4MEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL10624875 | 0.79 | ALOX5 (0.42) | PDK2PDK4MEN1KMT2ANPC1 | |
| SCHEMBL29473845 | 0.79 | CYP2C19 (0.38) | PDK2PDK4MEN1KMT2ANPC1 | |
| SCHEMBL7982101 | 0.77 | ALOX15 (0.46) | PDK2PDK4MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092029-A1 | LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE | SCRIPPS RESEARCH INST (US) | 2026-04-02 | — | — | US | claimed |
| EP-4584236-A1 | LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE | The Scripps Research Institute (US) | 2025-07-16 | — | — | EP | claimed |
| WO-2024054881-A1 | LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-03-14 | — | — | WO | claimed |
| US-6391365-B1 | FOR FOODSTUFFS, STIMULANTS AND ORAL HYGIENE PRODUCTS | HAARMAN & REIMER GMBH (DE) | 2002-05-21 | — | — | US | claimed |
| US-20260092029-A1 | LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE | SCRIPPS RESEARCH INST (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4584236-A1 | LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE | The Scripps Research Institute (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024091684-A1 | POLYSULFATE AND POLYSULFONATE POLYMERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024054881-A1 | LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2022243655-A1 | DIFUNCTIONAL BIO-BENZOXAZINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | JONES PAUL (GB) | 2022-11-24 | — | — | WO | disclosed |
| EP-3330255-B1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3330255-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2018-06-06 | — | — | EP | disclosed |
| US-20170327456-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-11-16 | — | — | US | disclosed |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2005-08-11 | — | — | US | disclosed |
| WO-2004074270-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| EP-0707575-B1 | USE OF DIHYDROBENZOFURANONES AS SCENTING INGREDIENTS | FIRMENICH & CIE (CH) | 2001-10-24 | — | — | EP | disclosed |
| WO-2001000775-A1 | BENZOLACTONES AS BLEACH ACTIVATORS | U.S. BORAX INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| US-4827845-A | FROM PHENOL OR ARYL ETHER, KETONE, CARBON MONOXIDE, ACID | ASHLAND OIL, INC. (US) | 1989-05-09 | — | — | US | disclosed |
| US-4333759-A | Herbicidal 5-cyano-2,3-dihydro-benzofuran-2-ones | FISONS LIMITED (GB) | 1982-06-08 | — | — | US | disclosed |
| US-4263037-A | 5-Cyano-2,3-dihydrobenzofurans useful as herbicides | FISONS LIMITED (GB) | 1981-04-21 | — | — | US | disclosed |
| EP-0007719-A2 | Cyanbenzofuran derivatives, processes for their preparation and their use in herbicidal compositions; cyanobenzene, benzodioxepine, benzodioxaphosphepine and benzodioxathiepine derivatives | FBC LIMITED (GB) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327456-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, TMEM109 | PDK2 2647/4885PDK4 2799/4885MEN1 4309/4885 |
| US-20260092029-A1 | LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE | CYP2B6, CYP2A6, CYP1A1 | PDK2 189/4885PDK4 308/4885MEN1 4698/4885 |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, RNASEH1, NSUN3 | PDK2 1642/4885PDK4 1458/4885MEN1 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.